
    
      Patients with follicular lymphoma who require therapy and have been previously untreated are
      eligible for this non-randomized, phase II study evaluating up front therapy with CHOP-R x 3
      cycles followed by zevalin and 4 additional weeks of rituxan.The complete response will be
      determined by combining IWC criteria and PET scanning.Secondary objectives include PET-CT
      conversion rate, frequency and severity of adverse events, duration of complete remission and
      time to next lymphoma therapy.
    
  